DK1051159T3 - Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis - Google Patents

Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis

Info

Publication number
DK1051159T3
DK1051159T3 DK98904121T DK98904121T DK1051159T3 DK 1051159 T3 DK1051159 T3 DK 1051159T3 DK 98904121 T DK98904121 T DK 98904121T DK 98904121 T DK98904121 T DK 98904121T DK 1051159 T3 DK1051159 T3 DK 1051159T3
Authority
DK
Denmark
Prior art keywords
leishmaniasis
treatment
oral administration
solid pharmaceutical
fosin
Prior art date
Application number
DK98904121T
Other languages
Danish (da)
English (en)
Inventor
Juergen Engel
Werner Sarlikiotis
Thomas Klenner
Peter Hilgard
Dieter Sauerbier
Eckhard Milsmann
Original Assignee
Zentaris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Ag filed Critical Zentaris Ag
Application granted granted Critical
Publication of DK1051159T3 publication Critical patent/DK1051159T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98904121T 1998-01-22 1998-01-22 Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis DK1051159T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (1)

Publication Number Publication Date
DK1051159T3 true DK1051159T3 (da) 2002-08-05

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98904121T DK1051159T3 (da) 1998-01-22 1998-01-22 Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis

Country Status (24)

Country Link
US (1) US6544551B1 (https=)
EP (1) EP1051159B1 (https=)
JP (1) JP2002501015A (https=)
KR (1) KR100517399B1 (https=)
CN (1) CN100413492C (https=)
AT (1) ATE215817T1 (https=)
AU (1) AU756805B2 (https=)
BR (1) BR9814772A (https=)
CA (1) CA2318260C (https=)
CZ (1) CZ299229B6 (https=)
DE (1) DE69804865T2 (https=)
DK (1) DK1051159T3 (https=)
ES (1) ES2175663T3 (https=)
HU (1) HUP0004363A3 (https=)
IL (1) IL136196A (https=)
NO (1) NO20003674D0 (https=)
NZ (1) NZ505648A (https=)
PL (1) PL189654B1 (https=)
PT (1) PT1051159E (https=)
SI (1) SI1051159T1 (https=)
SK (1) SK284839B6 (https=)
TR (1) TR200001717T2 (https=)
UA (1) UA68372C2 (https=)
WO (1) WO1999037289A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
WO2003090757A1 (en) * 2002-04-26 2003-11-06 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
JP2005535688A (ja) 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
CA2526586C (en) 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
BR112013012652A2 (pt) 2010-11-22 2016-09-06 Dafra Pharma Res & Dev Bvba forma de dosagem sólida de oleil fosfocolina para administração oral, forma de dosagem sólida, e método para a preparação de uma forma de dosagem sólida
AU2012272642B2 (en) 2011-06-24 2017-09-07 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
WO2014166941A1 (en) * 2013-04-08 2014-10-16 Academisch Medisch Centrum Miltefosin or perifosin for use in the treatment of ibd
WO2016042372A1 (en) 2014-09-17 2016-03-24 Steer Engineering Private Limited Effervescent composition and method of making it
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
WO2017098481A1 (en) 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
PL3965739T3 (pl) * 2019-04-12 2025-01-13 Oblita Therapeutics Bvba Postacie dawkowane będące tabletkami oleilofosfocholiny

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
IE59777B1 (en) * 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicaments
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Also Published As

Publication number Publication date
SI1051159T1 (en) 2002-10-31
PT1051159E (pt) 2002-09-30
HUP0004363A2 (hu) 2001-04-28
CA2318260C (en) 2006-11-21
CN100413492C (zh) 2008-08-27
CZ20002596A3 (cs) 2000-10-11
EP1051159A1 (en) 2000-11-15
EP1051159B1 (en) 2002-04-10
NO20003674L (no) 2000-07-18
NZ505648A (en) 2002-10-25
KR20010034311A (ko) 2001-04-25
HUP0004363A3 (en) 2002-12-28
JP2002501015A (ja) 2002-01-15
IL136196A (en) 2004-07-25
WO1999037289A1 (en) 1999-07-29
SK9862000A3 (en) 2000-11-07
DE69804865T2 (de) 2002-11-07
CN1283111A (zh) 2001-02-07
SK284839B6 (sk) 2005-12-01
TR200001717T2 (tr) 2000-11-21
PL189654B1 (pl) 2005-09-30
US6544551B1 (en) 2003-04-08
ATE215817T1 (de) 2002-04-15
PL342838A1 (en) 2001-07-16
BR9814772A (pt) 2000-10-24
DE69804865D1 (de) 2002-05-16
CA2318260A1 (en) 1999-07-29
CZ299229B6 (cs) 2008-05-21
IL136196A0 (en) 2001-05-20
ES2175663T3 (es) 2002-11-16
AU756805B2 (en) 2003-01-23
KR100517399B1 (ko) 2005-09-28
AU6212198A (en) 1999-08-09
UA68372C2 (en) 2004-08-16
NO20003674D0 (no) 2000-07-18

Similar Documents

Publication Publication Date Title
DK1051159T3 (da) Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis
DE69940769D1 (de) Orale flüssige zusammensetzungen
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
AP1414A (en) Controlled release galantamine composition.
DK1126828T3 (da) Oral indgivelse af adenosin-analoger
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
HUP0301349A2 (hu) IL-11-tartalmú készítmények
FI20011703A7 (fi) Jodidia ja jodaattia sisältävä stabiloitu oraalinen farmaseuttinen koostumus sekä menetelmä
DE69034226D1 (de) Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu
JO2663B1 (en) Abandronate is a large dose
BR0009476A (pt) Esteróides imunomoduladores, em particular hemidrato de 16 alfa-bromoepiandrosterona
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
BR0005392A (pt) Composição de dhea e processo
SE8006550L (sv) Farmakologisk komposition, samt sett for dess framstellning
BG104424A (en) Pseudopolymorphic forms of 2-[2-[4-[bis(4-fluorophenyl) methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
BG104673A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
ES2165727T3 (es) Composiciones de administracion por via oral con baja dosificacion de proteinas citotoxicas.
DK0817643T3 (da) Forbindelser og præparater til administration af aktive midler
UA32939A (uk) Сульфокамфокаїн, спосіб його виготовлення і спосіб підготовки обладнання для виготовлення сульфокамфокаїну
BR9908155A (pt) Composto, composição farmacêutica, uso do composto, e, processo para intensificar cognição em um sujeito sofrendo de cognição diminuìda
UA30970A (uk) Спосіб лікування пульпіту